PRKAA1 and metabolic dysfunction-associated steatotic liver disease: Pharmacological activators have been useful in identifying targets and processes downstream of AMPK and have potential for development as drugs to treat metabolic disorders such as Type 2 diabetes or non-alcoholic fatty liver disease [18–21].